Browse > Article

The Reverse Proteomics for Identification of Tumor Antigens  

Lee, Sang-Yull (Department of Biochemistry, School of Medicine, Pusan National University)
Jeoung, Doo-Il (School of Biological Sciences, College of Natural Sciences, Kangwon National University)
Publication Information
Journal of Microbiology and Biotechnology / v.17, no.6, 2007 , pp. 879-890 More about this Journal
Abstract
The identification of tumor antigens is essential for the development of anticancer therapeutic vaccines and clinical diagnosis of cancer. SEREX (serological analysis of recombinant cDNA expression libraries) has been used to identify such tumor antigens by screening sera of patients with cDNA expression libraries. SEREX-defined antigens provide markers for the diagnosis of cancers. Potential diagnostic values of these SEREX-defined antigens have been evaluated. SEREX is also a powerful method for the development of anticancer therapeutics. The development of anticancer vaccines requires that tumor antigens can elicit antigen-specific antibodies or T lymphocytes. More than 2,000 antigens have been discovered by SEFEX. Peptides derived from some of these antigens have been evaluated in clinical trials. This review provides information on the application of SEREX for identification of tumor-associated antigens (TAA) for the development of cancer diagnostics and anticancer therapeutics.
Keywords
DC-based anticancer vaccine; diagnostics; reverse proteomics; serological analysis of recombinant cDNA expression libraries; tumor-associated antigens;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 14  (Related Records In Web of Science)
연도 인용수 순위
1 Sakakura, C., K. Hasegawa, K. Miyagawa, S. Nakashima, T. Yoshikawa, S. Kin, Y. Nakase, S. Yazumi, H. Yamagishi, T. Okanoue, T. Chiba, and A. Hagiwara. 2005. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers. Clin. Cancer Res. 11: 6479-6488   DOI   ScienceOn
2 Salazar-Onfray, F., T. Nakazawa, V. Chhajlani, M. Petersson, K. Karre, G. Masucci, E. Celis, A. Sette, S. Southwood, E. Appella, and R. Kiessling. 1997. Synthetic peptides derived from the melanocyte-stimulating hormone receptor MC1R can stimulate HLA-A2-restricted cytotoxic T lymphocytes that recognize naturally processed peptides on human melanoma cells. Cancer Res. 57: 4348-4355
3 Tahara, K., K. Takesako, A. Sette, E. Celis, S. Kitano, and T. Akiyoshi. 1999. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 5: 2236-2241
4 Traversari, C., P. van der Bruggen, I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar- Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176: 1453-1457   DOI   ScienceOn
5 Vonderheide, R. H., W. C. Hahn, J. L. Schultze, and L. M. Nadler. 1999. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10: 673-679   DOI   ScienceOn
6 Wang, R. F., X. Wang, and S. A. Rosenberg. 1999. Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J. Exp. Med. 189: 1659-1668   DOI   ScienceOn
7 Watson, P. H., S. K. Chia, C. C. Wykoff, C. Han, R. D. Leek, W. S. Sly, K. C. Gatter, P. Ratcliffe, and A. L. Harris. 2003. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br. J. Cancer 88: 1065-1070   DOI   ScienceOn
8 Adrain, C., B. M. Murphy, and S. J. Martin. 2005. Molecular ordering of the caspase activation cascade initiated by the cytotoxic T lymphocyte/natural killer (CTL/NK) protease granzyme B. J. Biol. Chem. 280: 4663-4673   DOI
9 Butterfield, L. H., A. Koh, W. Meng, C. M. Vollmer, A. Ribas, V. Dissette, E. Lee , J. A. Glaspy, W. H. McBride, and J. S. Economou. 1999. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 59: 3134-3142
10 Benlalam, H., B. Linard, Y. Guilloux, A. Moreau-Aubry, L. Derre, E. Diez, B. Dreno, F. Jotereau, and N. Labarriere. 2003. Identification of five new HLA-B3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes. J. Immunol. 171: 6283-6289   DOI
11 Calhoun, R. F., B. Naziruddin, F. Enriquez-Rincon, B. F. Duffy, J. M. Ritter, S. Sundarsen, G. A. Patterson, J. D. Cooper, and T. Mohanakumar. 2000. Evidence for cytotoxic T lymphocyte response against human lung cancer: Reconstitution of antigenic epitope with peptide eluted from lung adenocarcinoma MHC class I. Surgery 128: 76-85   DOI   ScienceOn
12 Chen, Y. T., M. J. Scanlan, U. Sahin, O. Tureci, A. O. Gure, S. Tsang, B. Williamson, E. Stockert, M. Pfreundschuh, and L. J. Old. 1997. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 94L: 1914-1918
13 Cox, A. L., J. Skipper, Y. Chen, R. A. Henderson, T. L. Darrow, J. Shabanowitz, V. H. Engelhard, D. F. Hunt, and C. L. Slingluff. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716-719   DOI
14 Gueguen, M., J. J. Patard, B. Gaugler, F. Brasseur, J. C. Renauld, P. J. Van Cangh, T. Boon, and B. J. van den Eynde. 1998. An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol. 160: 6188-6194
15 Iwata, T., T. Fujita, N. Hirao, Y. Matsuzaki, T. Okada, H. Mochimaru, N. Susumu, E. Matsumoto, K. Sugano, N. Yamashita, S. Nozawa, and Y. Kawakami. 2005. Frequent immune responses to a cancer/testis antigen, CAGE, in patients with microsatellite instability-positive endometrial cancer. Clin. Cancer Res. 119: 3949-3957
16 Jager, D., E. Stockert, A. O. Gure, M. J. Scanlan, J. Karbach, E. Jager, A. Knuth, L. J. Old, and Y. T. Chen. 2001. Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. Cancer Res. 61: 2055-2061
17 Mischo, A., A. Wadle, K. Watzig, D. Jager, E. Stockert, D. Santiago, et al. 2003. Recombinant antigen expression on yeast surface (RAYS) for the detection of serological immune responses in cancer patients. Cancer Immun. 3: 5
18 Liu, G., H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, and J. S. Yu. 2004. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 64: 4980-4986   DOI   ScienceOn
19 Rivoltini, L., Y. Kawakami, K. Sakaguchi, S. Southwood, A. Sette, P. F. Robbins, et al. 1995. Induction of tumorreactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J. Immunol. 154: 2257-2265
20 Scanlan, M. J., Y. T. Chen, B. Williamson, A. O. Gure, E. Stockert, J. D. Gordan, O. Tureci, U. Sahin, M. Pfreundschuh, and L. J. Old. 1998. Characterization of human colon cancer antigens recognized by autologous antibodies. Int. J. Cancer 76: 652-658   DOI   ScienceOn
21 Somasundaram, R., R. Swoboda, L. Caputo, L. Otvos, B. Weber, P. Volpe, P. van Belle, S. Hotz, D. E. Elder, F. M. Marincola, L. Schuchter, D. Guerry, B. J. Czerniecki, and D. Herlyn. 2006. Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients. Cancer Res. 66: 3287-3293   DOI   ScienceOn
22 Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman.1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92: 11993-11997
23 Van den Eynde, B. J. and P. van der Bruggen. 1997. T cell defined tumor antigens. Curr Opin Immunol. 9: 684-693   DOI   ScienceOn
24 Wang, R. F., P. F. Robbins, Y. Kawakami, X. Q. Kang, and S. A. Rosenberg. 1995. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J. Exp. Med. 181: 799-804   DOI   ScienceOn
25 Lonchay, C., P. van der Bruggen, T. Connerotte, T. Hanagiri, P. Coulie, and D. Colau. 2004. Correlation between tumor regression and T cell responses in melanoma patients vaccinated with a MAGE antigen. Proc. Natl. Acad. Sci. USA 101: 14631-14638
26 Vissers, J. L., I. J. De Vries, M. W. Schreurs, L. P. Engelen, E. Oosterwijk, C. G. Figdor, and G. J. Adema. 1999. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res. 59: 5554-5559
27 Bjorkman, P. J. 1997. MHC restriction in three dimensions: A view of T cell receptor/ligand interactions. Cell 89: 167- 170   DOI   ScienceOn
28 Gong, J., N. Nikrui, D. Chen, S. Koido, Z. Wu, and Y. Tanaka. 2000. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165: 1705-1711   DOI
29 Groeper, C., F. Gambazzi, P. Zajac, L. Bubendorf, M. Adamina, R. Rosenthal, H. R. Zerkowski, M. Heberer, and G. C. Spagnoli. 2007. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int. J. Cancer 120: 337-343   DOI   ScienceOn
30 Sugita, S., H. Takase, C. Taguchi, Y. Imai, K. Kamoi, T. Kawaguchi, Y. Sugamoto, Y. Futagami, K. Itoh, and M. Mochizuki. 2006. Ocular infiltrating CD4+ T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest. Ophthalmol. Vis. Sci. 47: 2547-2554   DOI   ScienceOn
31 Line, A., Z. Slucka, A. Stengrevics, K. Silina, G. Li, and R. C. Rees. 2002. Characterisation of tumour-associated antigens in colon cancer. Cancer Immunol. Immunother. 51: 574-582   DOI   ScienceOn
32 Ichiki, Y., M. Takenoyama, M. Mizukami, T. So, M. Sugaya, M. Yasuda, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto. 2004. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer. J. Immunol. 172: 4844-4850   DOI
33 Maczek, C., T. G. Berger, B. Schuler-Thurner, E. S. Schultz, A. Hamann, P. R. Dunbar, V. Cerundolo, A. Steinkasserer, and G. Schuler. 2005. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase-, and influenza matrix peptide-specific CTL in HLA-A0201 melanoma patients. Int. J. Cancer 115: 450-455   DOI   ScienceOn
34 Tomkiel, J. E., H. Alansari, N. Tang, J. B. Virgin, X. Yang, P. VandeVord, et al. 2002. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer. Clin. Cancer Res. 8: 752-758
35 Muul, L. M., P. J. Spiess, E. P. Director, and S. A. Rosenberg. 1987. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J. Immunol. 138: 989-995
36 Steitz, J., S. Buchs, D. Tormo, A. Ferrer, J. Wenzel, C. Huber, T. Wolfel, M. Barbacid, M. Malumbres, and T. Tuting. 2006. Evaluation of genetic melanoma vaccines in cdk4-mutant mice provides evidence for immunological tolerance against authochthonous melanomas in the skin. Int. J. Cancer 118: 373-380   DOI   ScienceOn
37 Boon, T., O. G. Coulie, and B. Van den Eynde. 1997. Tumor antigens recognized by T cells. Immunol. Today 18: 267
38 Fernandez Madrid, F., R. L. Karvonen, M. J. Kraut, B. Czelusniak, and J. W. Ager. 1996. Autoimmunity to collagen in human lung cancer. Cancer Res. 56: 121-126
39 Boel, P., C. Wildmann, M. L. Sensi, R. Brasseur, J. C. Renauld, P. Coulie, T. Boon, and P. van der Bruggen. 1995. BAGE: A new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2: 167-175   DOI   ScienceOn
40 Jager, E., J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, D. Panicali, E. Hoffman, L. Pan, H. Oettgen, L. J. Old, and A. Knuth. 2006. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1- specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 103: 14453-14458
41 Scanlan, M. J., J. D. Gordan, B. Williamson, E. Stockert, N. H. Bander, V. Jongeneel, A. O. Gure, D. Jager, E. Jager, A. Knuth, Y. T. Chen, and L. J. Old. 1999. Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int. J. Cancer 83: 456-464   DOI   ScienceOn
42 Traversari, C., P. van der Bruggen, B. Van den Eynde, P. Hainaut, C. Lemoine, N. Ohta, L. Old, and T. Boon. 1992. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes. Immunogenetics 35: 145-152   DOI
43 Reich, N. C., M. Oren, and A. J. Levine. 1983. Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53. Mol. Cell. Biol. 3: 2143-2150   DOI
44 Grohmann, U., R. Bianchi, E. Ayroldi, M. L. Belladonna, D. Surace, and M. C. Fioretti. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158: 3593-3602
45 Walton, S. M., M. Gerlinger, O. de la Rosa, N. Nuber, A. Knights, A. Gati, M. Laumer, L. Strauss, C. Exner, N. Schalfer, M. Urosevic, R. Dummer, J. M. Tiercy, A. Mackensen, E. Jager, F. Levy, A. Kunth, D. Jager, and A. Zippelius. 2006. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J. Immunol. 177: 8212-8218   DOI
46 Posner, J. B. 1997. Paraneoplastic syndromes: A brief review. Ann. NY Acad. Sci. 835: 83-90   DOI
47 Koido, S., E. Hara, S. Homma, A. Torii, Y. Toyama, H. Kawahara, M. Watanabe, K. Yanaga, K. Fujise, H. Tajiri, J. Gong, and G. Toda. 2005. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11: 7891- 7900   DOI   ScienceOn
48 Kono, K., Y. Rongcun, J. Charo, F. Ichihara, E. Celis, A. Sette, E. Appella, T. Sekikawa, Y. Matsumoto, and R. Kiessling. 1998. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int. J. Cancer 78: 202-208   DOI   ScienceOn
49 Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, M. E. Dudley, S. L. Schwarz, P. J. Spiess, J. R. Wunderlich, M. R. Parkhurst, Y. Kawakami, C. A. Seipp, J. H. Einhorn, and D. E. White. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4: 321-327   DOI   ScienceOn
50 Scanlan, M. J., S. Welt, C. M. Gordon, Y. T. Chen, A. O. Gure, E. Stockert, A. A. Jungbluth, G. Ritter, D. Jager, E. Jager, A. Knuth, and L. J. Old. 2002. Cancer-related serological recognition of human colon cancer: Identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 62: 4041-4047
51 van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643- 1647   DOI
52 Jager, E., Y. T. Chen, J. W. Drijfhout, J. Karbach, M. Ringhoffer, D. Jager, M. Arand, H. Wada, Y. Noguchi, E. Stockert, L. J. Old, and A. Knuth. 1998. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 187: 265-270   DOI   ScienceOn
53 Lepage, S. and R. Lapointe. 2006. Melanosomal targeting sequences from gp100 are essential for MHC class IIrestricted endogenous epitope presentation and mobilization to endosomal compartments. Cancer Res. 66: 2423-2432   DOI   ScienceOn
54 Brandle, D., F. Brasseur, P. Weynants, T. Boon, and B. van den Eynde. 1996. A mutated HLA-A2 molecule recognized by autologous cytotoxic T lymphocytes on a human renal cell carcinoma. J. Exp. Med. 183: 2501-2508   DOI
55 Figueiredo, D. L., R. C. Mamede, R. Proto-Siqueira, L. Neder, W. A. Silva, and M. A. Zago. 2006. Expression of cancer testis antigens in head and neck squamous cell carcinomas. Head Neck 28: 614-619   DOI   ScienceOn
56 Ohkouchi, S., N. Kawamoto, M. Koga, F. Sakanashi, S. Shichijo, Y. Saijo, T. Nukiwa, K. Itoh, and A. Yamada. 2003. Identification of a CTL-directed epitope encoded by an intron of the putative tumor suppressor gene Testin of the common fragile site 7G region: A peptide vaccine candidate for HLA-B52+ and HLA-62+ cancer patients. Eur. J. Immunol. 33: 2964-2973   DOI   ScienceOn
57 Baurain, J. F., D. Colau, N. van Baren, C. Landry, V. Martelange, M. Vikkula, T. Boon, and P. G. Coulie. 2000. High frequency of autologous anti-melanoma CTL directed against an antigen generated by a point mutation in a new helicase gene. J. Immunol. 164: 6057-6066   DOI
58 Sundberg, E. J., M. W. Sawicki, S. Southwood, P. S. Andersen, A. Sette, and R. A. Mariuzza. 2002. Minor structural changes in a mutated human melanoma antigen correspond to dramatically enhanced stimulation of a CD4+ tumor-infiltrating lymphocyte line. J. Mol. Biol. 319: 449- 461   DOI   ScienceOn
59 Zhang, Y., N. Renkvist, Z. Sun, B. Schuler-Thurner, N. Glaichenhaus, G. Schuler, T. Boon, P. van der Bruggen, and D. Colau. 2005. Polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur. J. Immunol. 35: 1066-1075   DOI   ScienceOn
60 Wang, R. F., X. Wang, A. C. Atwood, S. L. Topalian, and S. A. Rosenberg. 1999. Cloning genes encoding MHC class II-restricted antigens: Mutated CDC27 as a tumor antigen. Science 284: 1351-1354   DOI
61 Greenberg, P. D. 1991. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49: 281-355   DOI
62 Sonn, C. H., H. R. Yoon , I. O. Seong, M. Chang, Y. C. Kim, H. Kang, S. Suh, and Y. S. Kim. 2006. MethA fibrosarcoma cells expressing membrane-bound forms of IL-2 enhance antitumor immunity. J. Microbiol. Biotechnol. 16: 1919- 1927   과학기술학회마을
63 Khong, H. T., J. C. Yang, S. L. Topalian, R. M. Sherry, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2004. Immunization of HLA-A0201 and/or HLA-DPbeta104 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27: 472-477   DOI   ScienceOn
64 Hunt, D. F., R. A. Henderson, J. Shabanowitz, K. Sakaguchi, H. Michel, N. Sevilir, A. L. Cox, E. Appella, and V. H. Engelhard. 1992. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 255: 1261-1263   DOI
65 Schmits, R., B. Cochlovius, G. Treitz, E. Regitz, R. Ketter, K. D. Preuss, B. F. Romeike, and M. Pfreundschuh. 2002. Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int. J. Cancer 98: 73-77   DOI   ScienceOn
66 Cho, B., H. Lee, S. Jeong, Y. J. Bang, H. J. Lee, K. S. Hwang, H. Y. Kim, Y. S. Lee, G. H. Kang, and D. I. Jeoung. 2003. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 307: 52-63   DOI   ScienceOn
67 Gambacorti-Passerini, C., F. Grignani, F. Arienti, P. P. Pandolfi, P. G. Pelicci, and G. Parmiani. 1993. Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells. Blood 81: 1369-1375
68 Scanlan, M. J., I. Gout, C. M. Gordon, B. Williamson, E. Stockert, A. O. Gure, D. Jager, Y. T. Chen, A. Mackay, M. J. O'Hare, and L. J. Old. 2001. Humoral immunity to human breast cancer: Antigen definition and quantitative analysis of mRNA expression. Cancer Immunity 1: 4
69 Heckel, D., N. Comtesse, N. Brass, N. Blin, K. D. Zang, and E. Meese. 1997. Novel immunogenic antigen homologous to hyaluronidase in meningioma. Hum. Mol. Genet. 6: 33-39   DOI
70 Rosenberg, S. A., B. S. Packard, P. M. Aebersold, D. Solomon, S. L. Topalian, S. T. Toy, P. Simon, M. T. Lotze, J. C. Yang, C. A. Seipp, et al. 1988. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. 1988. N. Engl. J Med. 319: 1676-1680   DOI   ScienceOn
71 Marchand, M., N. Van Baren, P. Weynants, V. Brichard, B. Dreno, M. H. Tessier, et al. 1999. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer 80: 219-230   DOI   ScienceOn
72 Ottaviani, S., Y. Zhang, T. Boon, and P. van der Bruggen. 2005. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol. Immunother. 54: 1214-1220   DOI   ScienceOn
73 Prins, R. M., S. K. Odesa, and L. M. Liau. 2003. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res. 63: 8487- 8491
74 Rivoltini, L., P. Squarcina, D. J. Loftus, C. Castelli, P. Tarsini, A. Mazzocchi, et al. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: Implication for more effective immunotherapy. Cancer Res. 59: 301-306
75 Rosenberg, S. A., J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, et al. 1999. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J. Immunol. 163: 1690-1695
76 Sahin, U., O. Tureci, H. Schmitt, B. Cochlovius, T. Johannes, R. Schmits, F. Stenner, G. Luo, I. Schobert, and M. Pfreundschuh. 1995. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92: 11810-11813
77 Thomas, C. M. and C. G. Sweep. 2001. Serum tumor markers: Past, state of the art, and future. Int. J. Biol. Markers 16: 73-86   DOI
78 Fay, J. W., A. K. Palucka, S. Paczesny, M. Dhodapkar, D. A. Johnston, S. Burkeholder, et al. 2006. Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells. Cancer Immunol. Immunother. 55: 1209-1218   DOI   ScienceOn
79 Van den Eynde, B., O. Peeters, O. De Backer, B. Gaugler, S. Lucas, and T. Boon. 1995. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J. Exp. Med. 182: 689-698   DOI   ScienceOn